Ketotifen and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus
Journal Title: Journal of Clinical and Molecular Endocrinology - Year 2017, Vol 2, Issue 1
Abstract
Objective: Mast cells found to be an important contributor to inflammation, obesity, diabetes and atherosclerosis. We evaluate the ability of ketotifen to reduce cardiovascular risk in patient with type 2 diabetes millets (T2DM). Method: In a randomized controlled study we recruited forty eight patients with T2DM from Internal Medicine Department at Tanta University Hospital, Egypt. They were classified in to three groups. Group 1: received glimepiride (GL) 3 mg/day alone; group 2: received GL 3 mg/day +ketotifen 1 mg once daily; group 3: received GL 3 mg/day +ketotifen 1 mg twice daily. Fasting blood samples were obtained before and 12 weeks after treatment for biochemical analysis of IL-6 and lipid profile with subsequent calculation of Castelli index 1 and atherogenic coefficient. Body mass index was also calculated for all patients. Data were analyzed by paired student's t-test and one way analysis of variance, p<0.05 was considered statistically significant. Results: The obtained data suggested that ketotifen in its twice daily dose significantly improves lipid profile and decreases IL-6 level, castelli index 1 and atherogenic coefficient. Conclusions: Mast cell stabilization with ketotifen can decrease the risk of diabetes associated cardiovascular complications
Authors and Affiliations
Sahar M El-Haggar, Wael F Farrag, Fedaa A Kotkata
Keywords
Related Articles
- EP ID EP305601
- DOI 10.21767/2572-5432.100035
- Views 55
- Downloads 0
Ketotifen and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus
Objective: Mast cells found to be an important contributor to inflammation, obesity, diabetes and atherosclerosis. We evaluate the ability of ketotifen to reduce cardiovascular risk in patient with type 2 diabetes millet...
Aromatase Inhibitors Combined with Growth Hormone: A Cost-effective Last Chance for Improving Boysâ Stature at the Near-End of Growth?
Two studies have recently shown a clear benefit of using nonsteroidal aromatase inhibitors (AIs) in combination with growth hormone (rhGH) in pubertal boys of very short stature (between -2.5 and - 3 SDS) who are approac...
False Positive TSH Receptor Binding Inhibitory Immunoglobulin in a Patient with Overt Hyperthyroidism Caused by Painless Thyroiditis
The diagnosis of Graves’s disease (GD) can be challenging in patients with atypical presentations of hyperthyroidism. Recently, TSH receptor antibody assays are proposed as first-line test for suspected GD. I here report...
The Other Legacy of Antonie Van Leeuwenhoek: The Polyamines
Antonie van Leeuwenhoek (1632-1723) left us two legacies; the first is the microscope and the second, the discovering of polyamines in the human semen.
Can Betatrophin be a New Biochemical Marker in the Diagnosis of Insulinoma?
Originating from the β cells of Langerhans islets, insulinoma has an incidence of 1 to 4 in one million in the general population, but is the most common tumor among pancreatic neuroendocrine tumors [1]. It can be life-t...